HVps37A status affects prognosis and cetuximab sensitivity in ovarian cancer

Clinical Cancer Research

Volumn 17, Issue 24, 2011, Pages 7816-7827

  Wittinger, Michael ^a   Vanhara, Petr ^a   El Gazzar, Ahmed ^a   Savarese Brenner, Bettina ^a   Pils, Dietmar ^a   Anees, Mariam ^a   Grunt, Thomas W ^a   Sibilia, Maria ^b   Holcmann, Martin ^b   Horvat, Reinhard ^a   Schemper, Michael ^a   Zeillinger, Robert ^a   Schöfer, Christian ^c   Dolznig, Helmut ^a   Horak, Peter ^a   Krainer, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Medical University of Vienna   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CETUXIMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PLATINUM COMPLEX; PROTEIN KINASE B; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VACUOLAR PROTEIN SORTING 37 HOMOLOGUE A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CONTROLLED STUDY; CYTOPLASM; DISEASE MARKER; DOWN REGULATION; DRUG EFFECT; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PROGNOSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84055211758     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0408     Document Type: Article

References (38)

1. Hynes NE, Horsch K, Olayioye MA, Badache A. The ErbB receptor tyrosine family as signal integrators. Endocr Relat Cancer 2001;8:151-9. (Pubitemid 32947637)
2. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54. (Pubitemid 40637826)
3. Bogdan S, Klambt C. Epidermal growth factor receptor signaling. Curr Biol 2001;11:R292-5. (Pubitemid 32324746)
4. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006;12:5268-72. (Pubitemid 44497237)
5. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003;284:99-110. (Pubitemid 36331969)
6. Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 2007;19:2013-23. (Pubitemid 47353811)
7. Maxfield FR, McGraw TE. Endocytic recycling. Nat Rev Mol Cell Biol 2004;5:121-32. (Pubitemid 38160255)
8. Katzmann DJ, Odorizzi G, Emr SD. Receptor downregulation and multivesicular-body sorting. Nat Rev Mol Cell Biol 2002;3:893-905. (Pubitemid 35477368)
9. Raiborg C, Rusten TE, Stenmark H. Protein sorting into multivesicular endosomes. Curr Opin Cell Biol 2003;15:446-55. (Pubitemid 36928047)
10. Katzmann DJ, Babst M, Emr SD. Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I. Cell 2001;106:145-55. (Pubitemid 32772626)
11. Xu Z, Liang L, Wang H, Li T, Zhao M. HCRP1, a novel gene that is downregulated in hepatocellular carcinoma, encodes a growth-inhibitory protein. Biochem Biophys Res Commun 2003;311:1057-66. (Pubitemid 37393426)
12. Bache KG, Slagsvold T, Cabezas A, Rosendal KR, Raiborg C, Stenmark H. The growth-regulatory protein HCRP1/hVps37A is a subunit of mammalian ESCRT-I and mediates receptor down-regulation. Mol Biol Cell 2004;15:4337-46. (Pubitemid 39122034)
13. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
14. Pils D, Pinter A, Reibenwein J, Alfanz A, Horak P, Schmid BC, et al. In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway. Br J Cancer 2007;96:485-91. (Pubitemid 46215221)
15. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008;27:3944-56. (Pubitemid 351913636)
16. Pennock S, Wang Z. Stimulation of cell proliferation by endosomal epidermal growth factor receptor as revealed through two distinct phases of signaling. Mol Cell Biol 2003;23:5803-15. (Pubitemid 36951342)
17. Haugh JM, Meyer T. Active EGF receptors have limited access to PtdIns(4,5)P(2) in endosomes: implications for phospholipase Cand PI 3-kinase signaling. J Cell Sci 2002;115:303-10. (Pubitemid 34145180)
18. Lee SW, Fang L, Igarashi M, Ouchi T, Lu KP, Aaronson SA. Sustained activation of Ras/Raf/mitogen-activated protein kinase cascade by the tumor suppressor p53. Proc Natl Acad Sci U S A 2000;97:8302-5. (Pubitemid 30639667)
19. Miaczynska M, Pelkmans L, Zerial M. Not just a sink: endosomes in control of signal transduction. Curr Opin Cell Biol 2004;16:400-6. (Pubitemid 38903146)
20. Tang D, Wu D, Hirao A, Lahti JM, Liu L, Mazza B, et al. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem 2002;277:12710-7. (Pubitemid 34952631)
21. Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 2002;12:9-18. (Pubitemid 135708299)
22. Raiborg C, Malerod L, Pedersen NM, Stenmark H. Differential functions of Hrs and ESCRT proteins in endocytic membrane trafficking. Exp Cell Res 2008;314:801-13. (Pubitemid 351191901)
23. Lu Q, Hope LW, Brasch M, Reinhard C, Cohen SN. TSG101 interaction with HRS mediates endosomal trafficking and receptor down-regulation. Proc Natl Acad Sci U S A 2003;100:7626-31. (Pubitemid 36760020)
24. Tanaka N, Kyuuma M, Sugamura K. Endosomal sorting complex required for transport proteins in cancer pathogenesis, vesicular transport, and non-endosomal functions. Cancer Sci 2008;99:1293-303. (Pubitemid 351761716)
25. Siwak DR, Carey M, Hennessy BT, Nguyen CT, McGahren Murray MJ, Nolden L, et al. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol 2010;2010:568938.
26. Sheng Q, Liu J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br J Cancer 2011;104:1241-5.
27. Crijns AP, Duiker EW, de Jong S, Willemse PH, van der Zee AG, de Vries EG. Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy. Int J Gynecol Cancer 2006;16 (Suppl 1):152-65.
28. Kimball KJ, Numnum TM, Kirby TO, Zamboni WC, Estes JM, Barnes MN, et al. Aphase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma. Gynecol Oncol 2008;111:95-101.
29. Lafky JM, Wilken JA, Baron AT, Maihle NJ. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 2008;1785:232-65.
30. Konner J, Schilder RJ, DeRosa FA, Gerst SR, Tew WP, Sabbatini PJ, et al. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol 2008;110:140-5.
31. Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, et al. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol 2009;113:21-7.
32. Secord AA, Blessing JA, Armstrong DK, Rodgers WH, Miner Z, Barnes MN, et al. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol 2008;108:493-9.
33. Peipp M, Dechant M, Valerius T. Effector mechanisms of therapeutic antibodies against ErbB receptors. Curr Opin Immunol 2008;20:436-43.
34. Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G. The biological properties of cetuximab. Crit Rev Oncol Hematol 2008;68:93-106.
35. de Souza AP, Bonorino C. Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. Expert Rev Anticancer Ther 2009;9:1317-32.
36. Mandic R, Rodgarkia-Dara CJ, Zhu L, Folz BJ, Bette M, Weihe E, et al. Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor. FEBS Lett 2006;580:4793-800. (Pubitemid 44286833)
37. Yoshida T, Okamoto I, Okabe T, Iwasa T, Satoh T, Nishio K, et al. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. Int J Cancer 2008;122:1530-8. (Pubitemid 351294961)
38. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002;21:6255-63.